Oncoinvent ASA【0RU5】銘柄情報

Oncoinvent ASA (0RU5) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

46.00

( - )

買値

46.00

売値

46.00

出来高

0.00

0.00 日の範囲 0.00

46.00 52 週間の範囲 4,600.00

時価総額

206.007M

前日終値

46.00

始値

時刻

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

kr 4,908

発行済株式数

4,478,412

配当利回り

PER

-39.88

1 株当たり利益 (EPS)

-1.25

歳入

28.07M

純利益

-155.07M

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phas... Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway. 詳細を表示

セクター

業界

ウェブサイト

www.oncoinvent.com

本社

Oslo, Norway

設立

Oncoinvent ASA is listed in the sector of the ロンドン証券取引所 with ticker 0RU5. The last closing price for Oncoinvent ASA was kr46. Over the last year, Oncoinvent ASA shares have traded in a share price range of kr 46.00 to kr 4,600.00.

Oncoinvent ASA currently has 4,478,412 shares in issue. The market capitalisation of Oncoinvent ASA is kr206.01 million. Oncoinvent ASA has a price to earnings ratio (PE ratio) of -39.88.

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE...

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	46	4600	46	884	1478.7360602	DE
52	46	4600	46	4608	132.20180174	DE
156	46	4600	46	85128	90.28862825	DE
260	46	4600	46	51439	88.43346916	DE

0RU5 - Frequently Asked Questions (FAQ)

What is the current Oncoinvent ASA share price?

The current share price of Oncoinvent ASA is kr 46.00

How many Oncoinvent ASA shares are in issue?

Oncoinvent ASA has 4,478,412 shares in issue

What is the market cap of Oncoinvent ASA?

The market capitalisation of Oncoinvent ASA is NOK 206.01M

What is the 1 year trading range for Oncoinvent ASA share price?

Oncoinvent ASA has traded in the range of kr 46.00 to kr 4,600.00 during the past year

What is the PE ratio of Oncoinvent ASA?

The price to earnings ratio of Oncoinvent ASA is -39.88

What is the cash to sales ratio of Oncoinvent ASA?

The cash to sales ratio of Oncoinvent ASA is 7.96

What is the registered address of Oncoinvent ASA?

The registered address for Oncoinvent ASA is Gullhaugveien 7, Oslo, Oslo, 0484

What is the Oncoinvent ASA website address?

The website address for Oncoinvent ASA is www.oncoinvent.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Oncoinvent ASA (0RU5)